Regarding serum albumin (ALB), our data confirm its robust prognostic role in melanoma immunotherapy response: levels remained consistently higher in the clinical benefit group across all time points, with T1 ALB ≥ 41.3 g/L independently associated with favorable treatment outcomes. This evidence concerns the gene ALB and melanoma.